


AJOVY[®]
(fremanezumab-vfrm)
injection 225 mg/1.5 mL



INTRODUCING THE AJOVY AUTOINJECTOR

AJOVY is indicated for the preventive treatment of migraine in adults.



97%

of HCP and patient evaluators found the AJOVY Autoinjector easy to use in two human factor studies (N=77)^{1*}

STEP 1

Uncap the autoinjector

With one hand, firmly pull the cap straight off the autoinjector (don't twist) and throw the cap away immediately.

These steps are not the full instructions for using the AJOVY Autoinjector. Please see the Instructions for Use in the full Prescribing Information.

*Two human factor studies assessed evaluators' ability to complete critical tasks in order to demonstrate use of the AJOVY Autoinjector in simulated-use sessions. When asked "Was the autoinjector easy to use?", 97% in study 1 (N=30) and 98% in study 2 (N=47) answered "Yes".¹

STEP 2

Place at a 90° angle

Place the autoinjector at a 90° angle against your skin at your chosen injection site.

STEP 3

Press down and hold autoinjector 10 seconds after second click

Press down on the autoinjector. You will hear a click. This means the injection has started and you should see the blue plunger move down. You will hear a second click. Remove autoinjector 10 seconds after.

Please provide proper training to patients and/or caregivers on the preparation and administration of the AJOVY Autoinjector. Available resources include Instructions For Use in the full Prescribing Information, and an Instructions For Use video that you can watch at AJOVYhcp.com.

IMPORTANT SAFETY INFORMATION

Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.

See additional Important Safety Information on the back page and full Prescribing Information in pocket.

teva

The **long-acting** anti-CGRP injection with the option of dosing only 4 times a year^{2*}

QUARTERLY



AJOVY 675 mg

Autoinjector

Sig: SC given as three 225 mg/1.5 mL injections every 3 months

Refills: 3

MONTHLY



AJOVY 225 mg

Autoinjector

Sig: SC 225 mg/1.5 mL once every month

Refills: 11

Please make sure to specify “autoinjector” when filling out your patient’s prescription for AJOVY.

- ✓ No titration needed
- ✓ No loading dose

*“Long-acting” defined as efficacy measured over a 12-week period following a 225 mg x 3 (675 mg) SC dose.²

CGRP: calcitonin gene-related peptide; **SC:** subcutaneous.

IMPORTANT SAFETY INFORMATION (continued)

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions ($\geq 5\%$ and greater than placebo) were injection site reactions.

Please see the full Prescribing Information for AJOVY in pocket.

References: 1. Data on file. Parsippany, NJ: Teva Pharmaceuticals USA, Inc. 2. AJOVY[®] (fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals, USA, Inc.